olprinone

Olprinone is a selective phosphodiesterase 3 inhibitor developed as a cardiotonic agent. It exerts positive inotropic and vasodilatory effects by increasing intracellular cyclic AMP (cAMP) levels in both cardiomyocytes and vascular smooth muscle cells, leading to increased myocardial contractility and reduced vascular resistance. Olprinone is primarily indicated for the treatment of acute heart failure and has been marketed in Japan since 1996. Additional pharmacological actions include augmentation of cerebral blood flow, inhibition of platelet aggregation, anti-inflammatory activity, bronchodilation, improvement of microcirculation, and attenuation of oxidative injury[1][3][5][6][7].

Brand names

Loprinone

Other names

olprinone hydrochlorideolprinone hydrochloride hydrate